76 related articles for article (PubMed ID: 15137932)
1. Focus on polypharmacy in schizophrenia: does anyone truly benefit?
Goff DC; Freudenreich O
Int J Neuropsychopharmacol; 2004 Jun; 7(2):109-11. PubMed ID: 15137932
[No Abstract] [Full Text] [Related]
2. Antipsychotic polypharmacy: never say never, but never say always.
Stahl SM
Acta Psychiatr Scand; 2012 May; 125(5):349-51. PubMed ID: 22506490
[No Abstract] [Full Text] [Related]
3. Antipsychotic polypharmacy: are two ever better than one?
Goff DC; Dixon L
Am J Psychiatry; 2011 Jul; 168(7):667-9. PubMed ID: 21724670
[No Abstract] [Full Text] [Related]
4. Emerging guidelines for the use of antipsychotic polypharmacy.
Stahl SM
Rev Psiquiatr Salud Ment; 2013; 6(3):97-100. PubMed ID: 23485567
[No Abstract] [Full Text] [Related]
5. Treatment resistance in schizophrenia.
Johnstone EC; Sandler R
BMJ; 1996 Feb; 312(7027):325-6. PubMed ID: 8611817
[No Abstract] [Full Text] [Related]
6. D2 antagonist augmentation in patients with a partial response to atypical antipsychotics.
Mazeh D; Melamed Y; Weizman A
Can J Psychiatry; 2004 Apr; 49(4):281-2. PubMed ID: 15147030
[No Abstract] [Full Text] [Related]
7. Antipsychotic Polypharmacy in Schizophrenia: Why Not?
Guinart D; Correll CU
J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32369690
[No Abstract] [Full Text] [Related]
8. New promises for schizophrenia therapy.
Sridhar N
Drug Discov Today; 2002 Feb; 7(4):215-6. PubMed ID: 11839513
[No Abstract] [Full Text] [Related]
9. Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence?
Stahl SM
Int J Neuropsychopharmacol; 2004 Jun; 7(2):113-6. PubMed ID: 14984629
[No Abstract] [Full Text] [Related]
10. Antipsychotic polypharmacy, part 1: Shotgun approach or targeted cotreatment?
Correll CU
J Clin Psychiatry; 2008 Apr; 69(4):674-5. PubMed ID: 18507487
[No Abstract] [Full Text] [Related]
11. [Polypharmacy in the treatment of schizophrenia].
Messer T; Tiltscher C; Schmauss M
Fortschr Neurol Psychiatr; 2006 Jul; 74(7):377-91. PubMed ID: 16804806
[TBL] [Abstract][Full Text] [Related]
12. Monotherapy versus polypharmacy for hospitalized psychiatric patients.
Strous RD; Lerner V
Am J Psychiatry; 2005 Mar; 162(3):631-2; author reply 632-3. PubMed ID: 15741496
[No Abstract] [Full Text] [Related]
13. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
Constantine RJ; Andel R; McPherson M; Tandon R
Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive versus monotherapeutic treatment for schizophrenia: addressing antipsychotic side effects.
Hazra M; Mamo DC; Remington G
Am J Psychiatry; 2008 Mar; 165(3):396-7; author reply 397-8. PubMed ID: 18316434
[No Abstract] [Full Text] [Related]
15. Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study.
Sneider B; Pristed SG; Correll CU; Nielsen J
Eur Neuropsychopharmacol; 2015 Oct; 25(10):1669-76. PubMed ID: 26256007
[TBL] [Abstract][Full Text] [Related]
16. A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia.
Suzuki T; Uchida H; Watanabe K; Yagi G; Kashima H
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):361-9. PubMed ID: 14751434
[TBL] [Abstract][Full Text] [Related]
17. Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia.
Xiang YT; Weng YZ; Leung CM; Tang WK; Ungvari GS
Pharmacopsychiatry; 2007 Mar; 40(2):47-52. PubMed ID: 17447172
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and nature of antipsychotic polypharmacy among inpatients with schizophrenia spectrum disorders at an Australian mental health service.
John AP; Gee T; Alexander S; Ramankutty P; Dragovic M
Australas Psychiatry; 2014 Dec; 22(6):546-50. PubMed ID: 25147317
[TBL] [Abstract][Full Text] [Related]
19. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia.
Suzuki T; Uchida H; Tanaka KF; Nomura K; Takano H; Tanabe A; Watanabe K; Yagi G; Kashima H
Int J Neuropsychopharmacol; 2004 Jun; 7(2):133-42. PubMed ID: 14741059
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
